European journal of drug metabolism and pharmacokinetics · 2026
Concentration-to-Dose Ratio Differences Between Once-Daily Tacrolimus Formulations: A Five-Year Real-World Pharmacokinetic Study in Kidney Transplantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Varga Adam, Borbasne Farkas Kornelia, Kalmar Nagy Karoly, Szakaly Peter
Аннотация
BACKGROUND AND OBJECTIVE: Tacrolimus is a cornerstone of immunosuppression after kidney transplantation; however, its narrow therapeutic window and substantial inter- and intra-individual pharmacokinetic variability complicate dose optimization. Extended-release tacrolimus (ER-Tac) and MeltDose® prolonged-release tacrolimus (LCP-Tac) formulations have been developed to improve bioavailability and stabilize drug exposure. The concentration-to-dose (C/D) ratio has emerged as a clinically relevant surrogate marker of tacrolimus metabolism and apparent clearance. We aimed to evaluate long-term differences in C/D ratio dynamics between once-daily tacrolimus formulations.
METHODS: In this single-center retrospective study, 100 de novo kidney transplant recipients (2015-2018) received either ER-Tac (n = 50) or LCP-Tac (n = 50). Tacrolimus trough concentrations, daily doses, and laboratory parameters were collected up to 60 months post-transplantation. Longitudinal pharmacokinetic assessment was performed using repeated C/D ratio measurements. Linear mixed-effects models adjusted for recipient age and time post-transplantation were used for analysis. Clinical outcomes included delayed graft function (DGF), biopsy-proven acute rejection (BPAR), new-onset diabetes after transplantation (NODAT), and mortality.
RESULTS: LCP-Tac-treated patients required significantly lower daily doses from month 3 onward (p < 0.001) while maintaining comparable trough concentrations. The C/D ratio was consistently higher in the LCP-Tac group, reaching statistical significance from month 12 (p = 0.015) and increasing further over time (p < 0.001), suggesting lower apparent tacrolimus clearance and/or greater dose-normalized exposure. A higher proportion of LCP-Tac measurements remained within the predefined therapeutic range throughout follow-up. No significant differences were observed in DGF, BPAR, NODAT, or mortality between groups.
CONCLUSION: LCP-Tac was associated with lower dose requirements and higher, more stable C/D ratios compared with ER-Tac, suggesting formulation-dependent differences in tacrolimus pharmacokinetics. The C/D ratio may serve as a simple, clinically applicable surrogate marker for long-term pharmacokinetic monitoring in kidney transplant recipients.
METHODS: In this single-center retrospective study, 100 de novo kidney transplant recipients (2015-2018) received either ER-Tac (n = 50) or LCP-Tac (n = 50). Tacrolimus trough concentrations, daily doses, and laboratory parameters were collected up to 60 months post-transplantation. Longitudinal pharmacokinetic assessment was performed using repeated C/D ratio measurements. Linear mixed-effects models adjusted for recipient age and time post-transplantation were used for analysis. Clinical outcomes included delayed graft function (DGF), biopsy-proven acute rejection (BPAR), new-onset diabetes after transplantation (NODAT), and mortality.
RESULTS: LCP-Tac-treated patients required significantly lower daily doses from month 3 onward (p < 0.001) while maintaining comparable trough concentrations. The C/D ratio was consistently higher in the LCP-Tac group, reaching statistical significance from month 12 (p = 0.015) and increasing further over time (p < 0.001), suggesting lower apparent tacrolimus clearance and/or greater dose-normalized exposure. A higher proportion of LCP-Tac measurements remained within the predefined therapeutic range throughout follow-up. No significant differences were observed in DGF, BPAR, NODAT, or mortality between groups.
CONCLUSION: LCP-Tac was associated with lower dose requirements and higher, more stable C/D ratios compared with ER-Tac, suggesting formulation-dependent differences in tacrolimus pharmacokinetics. The C/D ratio may serve as a simple, clinically applicable surrogate marker for long-term pharmacokinetic monitoring in kidney transplant recipients.